SEARCH

SEARCH BY CITATION

References

  • 1
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 2
    Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: Evolution in practice and trends, 1994–2004. Am J Transplant 2006; 6(5 Pt 2): 11111131.
  • 3
    Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10(1 Pt 2): 7784.
  • 4
    Halloran PF. Sirolimus and cyclosporin for renal transplantation. Lancet 2000; 356: 179180.
  • 5
    Sehgal SN, Bansbach CC. Rapamycin: In vitro profile of a new immunosuppressive macrolide. Ann N Y Acad Sci 1993; 685: 5867.
  • 6
    Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc 1991; 23: 32623264.
  • 7
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194202.
  • 8
    Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(3 Suppl): 7S14S.
  • 9
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302.
  • 10
    Gregory CR, Huie P, Shorthouse R et al. Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. Transplant Proc 1993; 25(1 Pt 1): 120121.
  • 11
    Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 1991; 338: 12971298.
  • 12
    Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311316.
  • 13
    Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 20012006.
  • 14
    Smith KD, Wrenshall LE, Nicosia RF et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 10371045.
  • 15
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus–tacrolimus combination immunosuppression. Lancet 2000; 355: 376377.
  • 16
    Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303309.
  • 17
    Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 22732280.
  • 18
    Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845852.
  • 19
    Flechner SM. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 2003; 35(3 Suppl): 118S121S.
  • 20
    Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 10701076.
  • 21
    Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 17761785.
  • 22
    Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514522.
  • 23
    Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation—a common practice. Nephrol Dial Transplant 2006; 21: 22562262.
  • 24
    Ahsan N, Johnson C, Gonwa T et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245250.
  • 25
    Hill AB. Statistical evidence and inference. In: HillAB, ed. Principles of medical statistics. London : The Lancet Limited, 1971: 309323.
  • 26
    Ekberg H, Tedesco-Silva H, Demirbas A et al. Symphony comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplanation. Am J Transplant 2006; 6: 83.
  • 27
    Study Comparing Sirolimus with Cyclosporine in a Calcineurin Inhibitor (CNI)-free regimen in Kidney Transplant Recipients. http://www.wyeth.com/ClinicalTrialListings (2006).
  • 28
    Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients. http://www.wyeth.com/ClinicalTrialListings (2006).